Sarepta Therapeutics AI Stock Analysis
Want to see SRPT full AI Analyst Report?
Sarepta Therapeutics (SRPT) AI Stock Analysis
Sarepta Therapeutics
(NASDAQ:SRPT)
The score is driven primarily by mixed financial performance: strong multi-year revenue growth and improved leverage, but highly volatile margins/earnings and only recently improved cash generation. Technicals are a notable drag with the stock trading below major moving averages and soft momentum. Valuation provides little support due to the very high P/E and no dividend yield, partly offset by an earnings call that included raised revenue guidance and cost discipline and a corporate event that removed a key legal overhang.
Sarepta Therapeutics Key Performance Indicators (KPIs)
Revenue by SegmentSplits revenue across business lines and markets — for example commercial product sales, collaboration or licensing income, and geographic regions — to reveal where growth is coming from and how diversified the business is. Helps investors see whether Sarepta depends mainly on commercial sales from a small set of drugs, benefits from partner deals or milestone payments, and how exposure to different markets or revenue types affects risk and upside.
Products revenue showed a big build into 2024 and then trended down into early‑2026, reflecting uneven Alevitus commercialization and timing-driven one‑time therapy dynamics; Collaboration & Other is extremely lumpy and Q1‑2026 contains a large non‑cash Roche item that materially inflates headline revenue. Management’s reiterated guidance and strong gross margins support financial stability, but underlying product momentum is gradual and dependent on demand recovery and small safety cohorts—so focus on product revenue trajectory and upcoming clinical/regulatory readouts, not the headline collaboration spikes.
Sarepta Therapeutics (SRPT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.72B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.74M
- Price to Earnings (P/E)
- 178.6
- Beta (1Y)
- 1.37
- Revenue Growth
- -18.95%
- EPS Growth
- 59.85%
- Country
- US
- Employees
- 835
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sarepta Therapeutics Business Overview & Revenue Model
Company Description
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company...
How the Company Makes Money
Sarepta primarily makes money by selling its commercial DMD therapies, generating product revenue from U.S. and other applicable market sales of EXONDYS 51, VYONDYS 53, AMONDYS 45 (exon-skipping therapies), and ELEVIDYS (a gene therapy). Revenue is d...
Sarepta Therapeutics Earnings Call Summary
The call conveyed focused optimism, supported by stabilized ELEVIDYS demand, strong PMO performance, raised revenue guidance, positive pipeline data, upcoming DM1 and FSHD readouts, non-GAAP profitability, and nearly $1 billion of cash and investments. These positives were partially offset by year-over-year revenue declines driven by lower ELEVIDYS sales, significant take-or-pay charges and related gross-margin pressure, a third-quarter GAAP operating loss, the termination of ENVISION enrollment, and continued uncertainty around near-term ELEVIDYS growth and the non-ambulatory label.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million and narrowed the range to $1.25 billion-$1.3 billion; ELEVIDYS revenue was $83 million in the third quarter and is expected in the fourth quarter to trend in line with Q3, while the PMO franchise is expected to remain strong. Full-year combined non-GAAP R&D and SG&A expense guidance was narrowed to between $800 million and $825 million. The company expects to submit an sBLA for the under-four population mid-next year, complete enrollment of ENDEAVOR Cohort eight by the end of this year and engage with FDA in Q1 2027, share DM1 and FSHD MAD data in the coming weeks, receive higher-dose data early next year, and generate Huntington’s disease proof-of-biology data sometime around mid-year next year.
Sarepta Therapeutics Financial Statement Overview
Summary
Revenue scaled materially over the long run, but profitability and margins have been highly volatile (notably the 2025 loss) and only near break-even in the latest TTM. Leverage has improved and the latest TTM shows positive operating and free cash flow, but the cash-flow history is inconsistent, making durability the key risk.
Income Statement
54NeutralBalance Sheet
61PositiveCash Flow
57Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.96B | 2.20B | 1.90B | 1.24B | 933.01M | 701.89M |
| Gross Profit | 1.10B | 1.32B | 1.58B | 1.09B | 793.02M | 604.84M |
| EBITDA | 155.20M | -647.97M | 316.89M | -453.69M | -594.85M | -317.41M |
| Net Income | 14.76M | -713.41M | 235.24M | -535.98M | -703.49M | -418.78M |
Balance Sheet | ||||||
| Total Assets | 3.17B | 3.35B | 3.96B | 3.26B | 3.13B | 3.15B |
| Cash, Cash Equivalents and Short-Term Investments | 878.78M | 939.65M | 1.35B | 1.68B | 1.99B | 2.12B |
| Total Debt | 1.05B | 1.04B | 1.34B | 1.40B | 1.62B | 1.15B |
| Total Liabilities | 1.64B | 2.21B | 2.44B | 2.41B | 2.74B | 2.22B |
| Stockholders Equity | 1.53B | 1.14B | 1.53B | 859.34M | 384.95M | 928.01M |
Cash Flow | ||||||
| Free Cash Flow | -31.60M | -307.45M | -352.74M | -588.34M | -357.60M | -481.66M |
| Operating Cash Flow | -17.12M | -205.48M | -205.79M | -500.99M | -325.35M | -443.17M |
| Investing Cash Flow | -424.30M | 69.64M | 755.56M | -165.80M | -1.05B | 495.41M |
| Financing Cash Flow | -38.73M | -168.34M | 124.81M | 125.00M | 232.51M | 561.57M |
Sarepta Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRPT, the sentiment is Negative. The current price of 16.07 is below the 20-day moving average (MA) of 17.95, below the 50-day MA of 18.59, and below the 200-day MA of 18.52, indicating a bearish trend. The MACD of -0.53 indicates Positive momentum. The RSI at 37.34 is Neutral, neither overbought nor oversold. The STOCH value of 9.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRPT.
Sarepta Therapeutics Risk Analysis
Sarepta Therapeutics disclosed 66 risk factors in its most recent earnings report. Sarepta Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSarepta Therapeutics Peers Comparison
Overall Rating
SRPT54Neutral
TSHA54Neutral
QURE50Neutral
RARE48Neutral
WVE45Neutral
SLDB42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 54Neutral | $1.72B | 178.56 | 1.04% | ― | -18.95% | 59.85% | |
| 54Neutral | $1.34B | -9.53 | -51.87% | ― | -13.07% | -23.02% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.67B | -6.72 | -96.34% | ― | 28.04% | 19.12% | |
| 48Neutral | $1.64B | -3.10 | 213.22% | ― | 15.76% | 12.63% | |
| 45Neutral | $617.33M | -2.92 | -44.48% | ― | -35.07% | -45.17% | |
| 42Neutral | $763.42M | -3.82 | -67.78% | ― | ― | 28.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics Inc. | 16.07 | -1.47 | -8.38% | |
| RARE | Ultragenyx Pharmaceutical, Inc. | 16.08 | -16.46 | -50.58% | |
| QURE | uniQure N.V. | 23.81 | -6.52 | -21.50% | |
| WVE | Wave Life Sciences Pte. Ltd | 3.13 | -4.02 | -56.22% | |
| SLDB | Solid Biosciences | 6.84 | 2.50 | 57.60% | |
| TSHA | Taysha Gene Therapies, Inc. | 4.10 | -0.02 | -0.49% |
Sarepta Therapeutics Corporate Events
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
PositiveOn September 23, 2026, Sarepta Therapeutics, its affiliate Sarepta Therapeutics Three, REGENXBIO, the Trustees of the University of Pennsylvania and Catalent entered into a settlement resolving patent infringement litigation and related appeals invol...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
